⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 12, 2024International Journal of Clinical PharmacyOpen Access

Levels of serum lipids predict responses to PD-L1 inhibitors as first-line treatment in small cell lung cancer: an observational study

Qiaoli Chen Ping Shu Yuan Xia Wei Zhang

View Full Paper

Ask AI

Bookmark

Share

Abstract

Immunotherapy provides new hope to individuals with small cell lung cancer (SCLC). Predicting biomarkers for clinical effects is crucial for SCLC patients receiving programed death-ligand 1 (PD-L1) inhibitor treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e58ba7b6db643587527973 https://doi.org/10.1007/s11096-024-01792-0

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Levels of serum lipids predict responses to PD-L1 inhibitor as first-line treatment in small cell lung cancer: an observational study2024
2Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)2025 · 4 citations
3Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study2024 · 8 citations
4Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer2024 · 9 citations
5What Are the Biomarkers for Immunotherapy in SCLC?Prognostic Study · 2021 · 47 citations